T-DXd: Clinical Trials

13 trials of T-DXd, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 recruiting, 2 active not recruiting, 1 completed, 1 not yet recruiting. 13 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 313Recruiting 9, Active not recruiting 2, Completed 1, Not yet recruiting 1

Follow T-DXd: new trials by email Literature Review of T-DXd trials Research Report on T-DXd

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma
Phase 3RecruitingSWOG Cancer Research Network5622027-03-092026-10-13
Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan
Dexamethasone, antiemetic premedication, T-DXd - Breast Cancer, Interstitial Lung Disease (ILD)
Phase 3Not yet recruitingMario Negri Institute for Pharmacological Research2442026-12-202026-10-19
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer
Phase 3RecruitingDaiichi Sankyo2002026-11-042026-11-17
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed - Non-small Cell Lung Cancer
Phase 3RecruitingDaiichi Sankyo6862025-10-242026-11-18
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
Trastuzumab Deruxtecan, Chemotherapy - Endometrial Cancer
Phase 3RecruitingDaiichi Sankyo7102025-09-302026-10-27
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel - Breast Neoplasms
Phase 3RecruitingMerck Sharp & Dohme LLC10002025-07-212026-11-03
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Trastuzumab Deruxtecan, Bevacizumab - Ovarian Cancer
Phase 3RecruitingDaiichi Sankyo5822025-03-192026-10-28
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab - Gastric Cancer, Gastroesophageal Junction Cancer
Phase 3RecruitingDaiichi Sankyo7262025-02-272026-08-10
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
T-DXd - Advanced Cancer, Metastatic Cancer
Phase 3RecruitingDaiichi Sankyo752024-01-052026-10-26
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Trastuzumab Deruxtecan - Breast Cancer
Phase 3RecruitingDaiichi Sankyo2502023-12-302026-06-12
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab - Breast Neoplasms, Breast Cancer
Phase 3Active not recruitingAstraZeneca9272021-10-252026-08-11
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Trastuzumab deruxtecan, Ramucirumab, Paclitaxel - Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Phase 3Active not recruitingDaiichi Sankyo4902021-05-212026-05-27
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Trastuzumab deruxtecan, Capecitabine, Lapatinib - Breast Cancer
Phase 3CompletedDaiichi Sankyo6082018-08-012026-02-27

Conditions studied

Breast Neoplasms (6)  ·  Stomach Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Endometrial Neoplasms (1)  ·  Lung Diseases, Interstitial (1)  ·  Neoplasm Metastasis (1)  ·  Ovarian Neoplasms (1)

Sponsors

Daiichi Sankyo (9)  ·  AstraZeneca (1)  ·  Mario Negri Institute for Pharmacological Research (1)  ·  Merck Sharp & Dohme LLC (1)  ·  SWOG Cancer Research Network (1)

Countries

United States (11)  ·  Italy (10)  ·  Spain (10)  ·  Brazil (9)  ·  China (9)  ·  Japan (9)  ·  South Korea (9)  ·  France (8)  ·  Germany (8)  ·  Taiwan (8)  ·  Poland (7)  ·  Australia (6)  ·  Belgium (6)  ·  Israel (6)  ·  Turkey (Türkiye) (6)

Top investigators

Mariya Rozenblit (1)

Results publications

PMID 37086745, PMID 38697155, PMID 40341124, PMID 40454632, PMID 41342740, PMID 42682104

NIH funding

2023 (3), 2025 (2), 2018 (1), U10CA180888 (1)